Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial.

New trials show promise for immune checkpoint blockers in early-stage lung cancer

A dendritic cell (DC) vaccine targeting patient-specific neoantigens to patients with resected non-small cell lung cancer (NSCLC).

April 18, 2024

QuantHealth Secures $15M for AI-Powered Clinical Trial Design

QuantHealth co-founders Arnon Horev and Orr (Ruti Benziman) What You Should Know: – QuantHealth, an Israeli-based AI-powered clinical trial design startup raises $15M in a

August 31, 2023

BridgeBio heart drug succeeds in pivotal study

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the

July 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.